NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NIAID E-220-2018-0-PCT-02 HIV-1 ENV Fusion Peptide Nanoparticle Carrier Conjugates and Their Use PCT PCT PCT/US2019/052419 Expired
NIAID E-248-2006-0-US-26 INTERGENIC SITES BETWEEN CONSERVED GENES IN THE GENOME OF MODIFIED VACCINIA ANKARA (MVA) VACCINIA VIRUS US DIV 16/579,276 Abandoned
NCI E-215-2018-0-CN-05 HALOGENATED 5-AZA-T-DCYD ANALOGS AND METHODS OF USE CN National Stage 201980062607.3 Pending
NCI E-133-2016-0-HK-09 FLT3-Specific Chimeric Antigen Receptors and Methods Using Same HK National Stage 19129998.1 Pending
NCI E-215-2018-0-EP-06 2'-HALOGENATED-4'- THIO-2'-DEOXY-5-AZACYTIDINE ANALOGS AND USE THEREOF EP National Stage 19782886.6 Pending
NCI E-215-2018-0-CA-04 2'-HALOGENATED-4'- THIO-2'-DEOXY-5-AZACYTIDINE ANALOGS AND USE THEREOF CA National Stage 3110224 Pending
NEI E-251-2012-3-AU-19 Methods For Generating Retinal Pigment Epithelium (RPE) Cells From Induced Pluripotent Stem Cells (IPSCS) AU DIV 2019236596 Abandoned
NCI E-131-2018-0-US-03 Fully Human Antibody Targeting Human CD123 For Cancer Threpeutics Development US ORD 16/578,063 10844128 Issued PDF
NCI E-131-2018-0-PCT-02 COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANTI-CD123 IMMUNOTHERAPY PCT PCT PCT/US2019/052226 Expired
NCI E-010-2019-0-PCT-02 Compositions And Methods For Modulation Of LMNA Expression PCT PCT PCT/US2019/052223 Expired
NHLBI E-186-2014-1-JP-09 SUPERAGONISTS, PARTIAL AGONISTS AND ANTAGONISTS OF INTERLEUKIN-2 JP DIV 2019-172064 Pending
NCI E-131-2018-0-JP-05 COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANTI-CD123 IMMUNOTHERAPY JP National Stage 2021-515623 Pending
NCI E-131-2018-0-AU-06 COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANTI-CD123 IMMUNOTHERAPY AU National Stage 2019343184 Pending
NCI E-131-2018-0-CN-07 COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANTI-CD123 IMMUNOTHERAPY CN National Stage 201980076357.9 Pending
NCI E-067-2017-0-US-08 METHODS OF ISOLATING NEOANTIGEN-SPECIFIC T CELL RECEPTOR SEQUENCES US National Stage 16/495,508 11898207 Issued PDF
NCI E-248-2020-0-US-01 Protein Panels For The Early Diagnosis/Prognosis Of Aggressive Prostate Cancer US 62/888,890 Abandoned
NCI E-168-2018-0-US-01 METHODS OF ISOLATING T CELL POPULATIONS US 62/902,184 Abandoned
CC E-076-2017-0-US-03 METHOD AND SYSTEM OF BUILDING HOSPITAL-SCALE CHEST X-RAY DATABASE FOR ENTITY EXTRACTION AND WEAKLY-SUPERVISED CLASSIFICATION AND LOCALIZATION OF COMMON THORAX DISEASES US National Stage 16/495,012 11583239 Issued PDF
NCI E-205-2018-0-PCT-02 Bicistronic Chimeric Antigen Receptor Constructs Targeting CD19 And CD20 PCT PCT PCT/US2019/051517 Expired
NCI E-176-2022-0-US-01 Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease US 62/901,638 Expired
NCATS E-203-2012-0-US-12 METHODS AND COMPOSITIONS FOR THE INHIBITION OF PIN1 US CON 16/570,470 11129835 Issued PDF
NCI E-182-2019-0-US-01 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER US 62/900,240 Abandoned
NEI E-227-2018-0-US-01 Metformin For The Treatment Of Age-related Retinal Degeneration US 62/899,899 Abandoned
NCI E-148-2011-0-HK-37 Anti-Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptors And Use Of Same For The Treatment Of Cancer HK EP 19129515.3 Issued
NHGRI E-122-2017-0-US-01 CANCER DETECTION AND CLASSIFICATION US 62/898,670 Abandoned
NCI E-016-2019-0-EP-04 Methods Of Decreasing Influenza-induced Lethality Using Gastrin Releasing Peptide (GRP) Or Gastrin Releasing Peptide Receptor (GRPR) Antagonists EP National Stage 19859381.6 Issued
NIAAA E-140-2014-0-AU-11 PYRAZOLE DERIVATIVES AND THEIR USE AS CANNABINOID RECEPTOR MEDIATORS AU DIV 2019227889 Issued
NCI E-016-2019-0-PCT-02 Methods Of Decreasing Influenza-induced Lethality Using Gastrin Releasing Peptide (GRP) Or Gastrin Releasing Peptide Receptor (GRPR) Antagonists PCT PCT PCT/US2019/050312 Expired
NCI E-030-2022-0-US-01 Anti-Viral Compositions And Methods Of Making And Using US 62/898,383 Abandoned
NIDA E-053-2016-2-PCT-02 DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF PCT PCT PCT/US2019/050165 Expired
NIDA E-053-2016-2-EP-05 DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF EP National Stage 19773300.9 Pending
NIDA E-053-2016-2-CA-04 DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF CA National Stage 3111785 Pending
NHLBI E-222-2022-7-US-01 Catheters and Manipulators with Articulable Ends US CIP 16/563,925 12133962 Issued PDF
NCI E-266-2011-0-HK-35 T Cell Receptors Recognizing HLA-A1-or HLA-CW7- Restricted Mage HK CN 19129278.8 Issued
NIAID E-150-2022-0-PCT-02 Compositions And Methods For Preventing And/or Treating Filarial Disease PCT PCT PCT/US2019/049869 Expired
NIAID E-150-2022-0-US-06 Compositions And Methods For Preventing And/or Treating Filarial Disease US National Stage 17/273,212 Pending
NIAID E-150-2022-0-EP-05 Compositions And Methods For Preventing And/or Treating Filarial Disease EP National Stage 19857011.1 Pending
NIAID E-150-2022-0-AU-03 Compositions And Methods For Preventing And/or Treating Filarial Disease AU National Stage 2019336212 Pending
NIAID E-150-2022-0-CA-04 Compositions And Methods For Preventing And/or Treating Filarial Disease CA National Stage 3110571 Pending
NCI E-230-2020-0-PCT-02 Recurrence Gene Signature Across Multiple Cancer Types PCT PCT PCT/US2019/049688 Expired
NIBIB E-006-2016-0-US-06 SYSTEMS AND METHODS FOR INSTANT TOTAL INTERNAL REFLECTION FLUORESCENCE/ STRUCTURED ILLUMINATION MICROSCOPY US CON 16/559,805 10914933 Issued PDF
NIAID E-178-2014-2-US-04 Self-Assembling Bi-component Nanoparticles For Display Of Co-assembled Trimeric Antigens US DIV 16/557,894 11459360 Issued PDF
NIAID E-048-2020-0-US-01 COMPOSITIONS INCLUDING IGG Fe MUTATIONS AND USES THEREOF US 62/894,488 Abandoned
NCATS E-084-2020-0-US-01 Preparation Of Benzene-1,4-disulfonamide Derivatives Useful As Therapeutic TRPML1 Receptor Modulators US 62/894,289 Abandoned
NCI E-132-2012-0-US-11 Altering the lmmundominance Hierarchy Using a DNA Vaccine Expressing Conserved Regions US DIV 16/554,133 11167025 Issued PDF
NINDS E-252-2016-1-US-03 DIAGNOSING COL6-RELATED DISORDERS AND METHODS FOR TREATING SAME US National Stage 16/315,278 11655470 Issued PDF
NIAID E-181-2016-0-US-03 ZIKA VIRUS VACCINES US National Stage 16/334,099 10898566 Issued PDF
NCI E-139-2018-0-AU-04 WATER SOLUBLE NOVEL CYANINE FLUOROPHORE WITH TUNABLE PROPERTIES BETWEEN NEAR IR AND SWIR REGION FOR IN VIVO IMAGING AU National Stage 2019325658 Issued
NCI E-146-2018-0-PCT-02 METHOD FOR TREATING GLIOBLASTOMA PCT PCT PCT/US2019/048040 Expired
NCI E-139-2018-0-PCT-02 Water Soluble Novel Cyanine Fluorophore With Tunable Optical Properties Between Near IR And SWIR Region For In Vivo Imaging PCT PCT PCT/US2019/047972 Expired